Epoxylipids and soluble epoxide hydrolase in heart diseases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F22%3A00556810" target="_blank" >RIV/67985823:_____/22:00556810 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/22:00081916 RIV/00216208:11130/22:10434794
Result on the web
<a href="https://doi.org/10.1016/j.bcp.2021.114866" target="_blank" >https://doi.org/10.1016/j.bcp.2021.114866</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bcp.2021.114866" target="_blank" >10.1016/j.bcp.2021.114866</a>
Alternative languages
Result language
angličtina
Original language name
Epoxylipids and soluble epoxide hydrolase in heart diseases
Original language description
Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manip-ulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epox-ylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ven-tricular tachycardia, and heart failure.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30105 - Physiology (including cytology)
Result continuities
Project
<a href="/en/project/GA18-03207S" target="_blank" >GA18-03207S: Cardiac ischemic tolerance of spontaneously hypertensive rats expressing human C-reactive protein.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biochemical Pharmacology
ISSN
0006-2952
e-ISSN
1873-2968
Volume of the periodical
195
Issue of the periodical within the volume
Jan
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
114866
UT code for WoS article
000777271600005
EID of the result in the Scopus database
2-s2.0-85120733144